1
项与 Malaria vaccines(Biological Mimetics, Inc.) 相关的临床试验Phase I, dose-escalating, randomized, comparator-controlled trial of the safety, tolerability, and immunogenicity of the co-administration of transmission-blocking vaccines (R0.6C-AlOH/ Matrix-M™ with Pfs230D1 EPA/Matrix-M™) and individual comparators (R0.6C-AlOH/ Matrix-M™; ProC6C-AlOH/ Matrix-M™ and Pfs230D1 EPA/Matrix-M™) against Plasmodium falciparum in adults in Mali: TBVax2
100 项与 Malaria vaccines(Biological Mimetics, Inc.) 相关的临床结果
100 项与 Malaria vaccines(Biological Mimetics, Inc.) 相关的转化医学
100 项与 Malaria vaccines(Biological Mimetics, Inc.) 相关的专利（医药）
780
项与 Malaria vaccines(Biological Mimetics, Inc.) 相关的文献（医药）2025-05-01·The Lancet Infectious Diseases
RH5.1/Matrix-M: highlighting blood-stage malaria vaccines
Article
作者: Palacpac, Nirianne Marie Q ; Horii, Toshihiro
Blood-stage vaccines have not gained much support as a standalone, due in part to disappointing results from earlier clin. trials that underscored hurdles in achieving notable vaccine efficacy.The completion of the trial and analyses of trial outcomes are much awaited.These continuing efforts for next-generation malaria vaccines provide the necessary visibility to interest funders and industry in a disease that still primarily affects low-income and middle-income countries.
Meeting report: Expert consultation on late arresting replication competent (LARC) malaria sporozoite vaccine research & development
Article
作者: McGugan, Glen ; Mo, Annie X ; Pesce, John T
In June 2024, the National Institute of Allergy and Infectious Diseases (NIAID) convened an expert consultation to guide strategic priorities for the research and development of next-generation whole Plasmodium falciparum sporozoite vaccine candidates. The focus was on genetically attenuated, late (liver stage) arresting replication competent (LARC) sporozoite vaccines. The meeting reviewed the World Health Organization (WHO) Preferred Product Characteristics (PPCs) for future malaria vaccines and drew lessons from previous malaria vaccine R&D and implementation efforts. Key discussions centered on critical features related to the Target Product Profiles (TPP) of LARC vaccines for various specified indications and relevant development strategies. The consultation identified knowledge gaps and suggested priorities and opportunities for future research and product development for LARC malaria sporozoite vaccines.
2025-04-01·Trends in Parasitology
Having your cake and eating it too – a new target for sporozoite-neutralising mAbs
Article
作者: Kaczmarski, Joe A ; Jackson, Colin J ; Cockburn, Ian A
Current malaria vaccines provide suboptimal, waning protection. Dacon et al. identify a protective post-translationally modified epitope on Plasmodium sporozoites that is absent from current vaccines. This discovery deepens our understanding of Plasmodium biology and may inform the development of improved vaccines and complementary prophylactic monoclonal antibodies.
100 项与 Malaria vaccines(Biological Mimetics, Inc.) 相关的药物交易
